Myeloma in Elderly Patients: When Less Is More and More Is More. Review uri icon

Overview

abstract

  • Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.

publication date

  • January 1, 2017

Research

keywords

  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Transplantation, Autologous

Identity

PubMed Central ID

  • PMC6619424

Scopus Document Identifier

  • 85042257982

Digital Object Identifier (DOI)

  • 10.1200/EDBK_175171

PubMed ID

  • 28561667

Additional Document Info

volume

  • 37